Efficacy and tolerability of perampanel as add‐on therapy in Dravet syndrome: A prospective real‐world study
In the neurology clinic of Shenzhen Children's Hospital, 21 children with Dravet syndrome were administered perampanel. Perampanel, as a novel anti-seizure medication approved for focal and generalized epilepsies as add-on therapy, showed sufficient efficacy and a satisfactory safety and tolerability profile in this study.
Authors
- Dezhi Cao (ORCID: https://orcid.org/0000-0002-7424-8063)
- Dongfang Zou (ORCID: https://orcid.org/0000-0001-6726-8704)
- Jiahui Mai (ORCID: https://orcid.org/0000-0002-1734-8316)
- Xueyan Cao (ORCID: https://orcid.org/0000-0002-1431-396X)
- Huafang Zou (ORCID: https://orcid.org/0000-0003-3252-4995)
- Xin Ding (ORCID: https://orcid.org/0000-0001-6055-5292)
- Jianxiang Liao (ORCID: https://orcid.org/0000-0002-2514-5340)
- Hong Chen (ORCID: https://orcid.org/0000-0002-4765-2642)
- Yanwei Zhu
- Han Wang (ORCID: https://orcid.org/0000-0003-4709-2363)
Institutions
- Shenzhen Children's Hospital (CN)
Publication Details
- Journal
- Epilepsia Open
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1002/epi4.70058
- Citations
- 1
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Sanming Project of Medicine in Shenzhen